• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Annovis Bio Inc.

    5/1/25 5:20:16 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email
    DEFA14A 1 tm252538d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.     )

     

    Filed by the Registrant  x

     

    Filed by a Party other than the Registrant  ¨

     

    Check the appropriate box:

     

    ¨   Preliminary Proxy Statement

     

    ¨   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨   Definitive Proxy Statement

     

    x    Definitive Additional Materials

     

    ¨    Soliciting Material under §240.14a-12

     

    Annovis Bio, Inc.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x   No fee required.

     

    ¨    Fee paid previously with preliminary materials.

     

    ¨    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

     

     

    GRAPHIC

    ANNOVIS BIO, INC. PLEASE VOTE NOW! ANNOVIS BIO, INC. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to: https://web.viewproxy.com/annovisbio/2025 To vote your proxy while visiting this site, you will need the 11 digit control number in the box on this page. This communication presents only an overview of the more complete proxy materials that are available to you on the internet. This is not a Proxy Card. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or Email copy of the proxy material, you must request one, there is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 10, 2025. TOORDER PAPER MATERIALS,USEONE OF THE FOLLOWING METHODS. Internet: https://web.viewproxy.com/annovisbio/2025 Phone: 1-877-777-2857 Email: [email protected] * If requesting material by Email, please send a blank Email with the 11 digit control number (located below) in the subjectline. No other requests, instructions OR other inquiries should be included with your Email requesting material. Scan QR Code for DigitalVoting CONTROL NUMBER SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting and Proxy Statement & Form 10-K. Important Notice Regarding the Availability of Proxy Materialsforthe Stockholders Meeting To Be HeldOn June 17, 2025 For Stockholders of record as of April 28, 2025. Tuesday, June 17, 2025, 10:00 AM Eastern Time To be held virtually Annual Meeting of Stockholders

    GRAPHIC

    Annovis Bio, Inc. THE BOARD OF DIRECTORS RECOMMENDS A VOTE: “FOR” ON PROPOSALS 1 AND 2. Proposal 1: To elect the five director nominees named in the accompanying Proxy Statement; 01 Michael Hoffman 02 Maria Maccecchini 03 Claudine Bruck 04 Reid McCarthy 05 Mark White Proposal 2: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and Note: To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof. Annual Meeting of Stockholders

    GRAPHIC

    Get informed before you vote *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID-JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 148,294 322,224 1 OF 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX ANNOVIS BIO, INC. 2025 Annual Meeting Vote by June 16, 2025 11:59 PM ET You invested in ANNOVIS BIO, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 17, 2025. View the Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 03, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* June 17, 2025 10:00 AM EST Annual Meeting to be held virtually To attend, you must register as a Beneficial Holder at the below URL: https://web.viewproxy.com/annovisbio/2025

    GRAPHIC

    Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID-JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. ANNOVIS BIO, INC. 2025 Annual Meeting Vote by June 16, 2025 11:59 PM ET 1. Election of Directors Nominees: 01 Michael Hoffman 03 Claudine Bruck 05 Mark White 02 Maria Maccecchini 04 Reid McCarthy For 2 To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and For NOTE: To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.

    Get the next $ANVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANVS

    DatePrice TargetRatingAnalyst
    2/10/2025Buy → Hold
    D. Boral Capital
    10/25/2024$25.00Hold → Buy
    Maxim Group
    12/29/2023$36.00Buy
    Canaccord Genuity
    7/7/2021$45.00 → $150.00Buy
    Maxim Group
    More analyst ratings

    $ANVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

      SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

      11/28/23 4:05:14 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Annovis Bio Inc.

      SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

      11/8/23 7:02:36 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

      MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

      11/7/24 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Andrew Walsh as Vice President Finance

      BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.  "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a

      12/1/23 7:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director White Mark K.

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:18:10 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mccarthy Reid

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:17:22 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Maccecchini Maria-Luisa gifted 30,000 shares, decreasing direct ownership by 3% to 1,068,459 units (SEC Form 4)

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:16:55 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ANVS
    SEC Filings

    See more

    $ANVS
    Financials

    Live finance-specific insights

    See more

    $ANVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

      MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the "Notice") from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholde

      3/27/25 4:30:00 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

      MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. "We are at a pivotal moment in our company's journey as we have entered the late clinical stages for both Alzheimer's and Parkinson's. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications," commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. "A

      3/25/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Annovis Bio Inc.

      DEFA14A - Annovis Bio, Inc. (0001477845) (Filer)

      5/1/25 5:20:16 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Annovis Bio Inc.

      DEF 14A - Annovis Bio, Inc. (0001477845) (Filer)

      4/30/25 5:20:39 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      3/27/25 4:35:31 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

      Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

      10/5/21 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio downgraded by D. Boral Capital

      D. Boral Capital downgraded Annovis Bio from Buy to Hold

      2/10/25 8:18:59 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio upgraded by Maxim Group with a new price target

      Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

      10/25/24 7:56:01 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Annovis Bio with a new price target

      Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00

      12/29/23 7:03:31 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care